{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:26:54Z","timestamp":1793647614145,"version":"4.5.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZB20240900"],"award-info":[{"award-number":["GZB20240900"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82241232"],"award-info":[{"award-number":["82241232"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01666-6","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T12:12:14Z","timestamp":1738930334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib\/II trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Gang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Chen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Xiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Feng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Sheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Guan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Xia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Chao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Sheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Li","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qiang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"1","key":"1666_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37\u201350.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1666_CR2","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832\u201342.","journal-title":"Lancet Oncol"},{"issue":"17","key":"1666_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"36","key":"1666_CR4","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu C, Lee SH, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35(36):4050\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1666_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"issue":"24","key":"1666_CR6","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1200\/JCO.23.02172","volume":"42","author":"O Hamid","year":"2024","unstructured":"Hamid O, Lewis KD, Weise A, et al. Phase I study of Fianlimab, a human lymphocyte activation Gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma. J Clin Oncol. 2024;42(24):2928\u201338.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1666_CR7","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","volume":"29","author":"JJ Luke","year":"2023","unstructured":"Luke JJ, Patel MR, Blumenschein GR, et al. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023;29(11):2814\u201324.","journal-title":"Nat Med"},{"issue":"2","key":"1666_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122\u201333.","journal-title":"N Engl J Med"},{"issue":"5","key":"1666_CR9","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","volume":"11","author":"SJ Dovedi","year":"2021","unstructured":"Dovedi SJ, Elder MJ, Yang C, et al. Design and efficacy of a monovalent bispecific PD-1\/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells. Cancer Discov. 2021;11(5):1100\u201317.","journal-title":"Cancer Discov"},{"issue":"9","key":"1666_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24(9):1415\u201322.","journal-title":"Nat Immunol"},{"issue":"5","key":"1666_CR11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","volume":"55","author":"T Maruhashi","year":"2022","unstructured":"Maruhashi T, Sugiura D, Okazaki IM, et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity. 2022;55(5):912\u201324. e8.","journal-title":"Immunity"},{"issue":"1","key":"1666_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jaad.2019.03.012","volume":"81","author":"WJ Lee","year":"2019","unstructured":"Lee WJ, Lee YJ, Choi ME, et al. Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes. J Am Acad Dermatol. 2019;81(1):219\u201327.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1666_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s40425-019-0752-4","volume":"7","author":"YQ Wang","year":"2019","unstructured":"Wang YQ, Zhang Y, Jiang W, et al. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. J Immunother Cancer. 2019;7(1):298.","journal-title":"J Immunother Cancer"},{"key":"1666_CR14","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3389\/fonc.2019.01334","volume":"9","author":"C Minichsdorfer","year":"2019","unstructured":"Minichsdorfer C, Oberndorfer F, Krall C, et al. PD-L1 expression on tumor cells is associated with a poor outcome in a cohort of caucasian nasopharyngeal carcinoma patients. Front Oncol. 2019;9:1334.","journal-title":"Front Oncol"},{"issue":"16","key":"1666_CR15","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","volume":"187","author":"AR Cillo","year":"2024","unstructured":"Cillo AR, Cardello C, Shan F, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity. Cell. 2024;187(16):4373\u2013e8815.","journal-title":"Cell"},{"issue":"16","key":"1666_CR16","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews LP, Butler SC, Cui J, et al. LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity. Cell. 2024;187(16):4355\u2013e7222.","journal-title":"Cell"},{"key":"1666_CR17","doi-asserted-by":"crossref","unstructured":"Yu X, Huang X, Chen X et al. Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. MAbs. 2019;11(6):1139-48.","DOI":"10.1080\/19420862.2019.1629239"},{"issue":"21","key":"1666_CR18","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.18632\/oncotarget.26771","volume":"10","author":"BJ Chen","year":"2019","unstructured":"Chen BJ, Dashnamoorthy R, Galera P, et al. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. Oncotarget. 2019;10(21):2030\u201340.","journal-title":"Oncotarget"},{"issue":"17","key":"1666_CR19","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.23.01636","volume":"42","author":"S Hegewisch-Becker","year":"2024","unstructured":"Hegewisch-Becker S, Mendez G, Chao J, et al. First-line nivolumab and relatlimab plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma: the phase II RELATIVITY-060 study. J Clin Oncol. 2024;42(17):2080\u201393.","journal-title":"J Clin Oncol"},{"key":"1666_CR20","doi-asserted-by":"crossref","unstructured":"Schoffski P, Tan DSW, Martin M et al. Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) +\/- anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022;10(2).","DOI":"10.1136\/jitc-2021-003776"},{"issue":"5","key":"1666_CR21","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-22-1449","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, LoRusso PM, Wong DJ, et al. A phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance. Clin Cancer Res. 2023;29(5):888\u201398.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1666_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"FH Wang","year":"2021","unstructured":"Wang FH, Wei XL, Feng J, et al. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;39(7):704\u201312.","journal-title":"J Clin Oncol"},{"key":"1666_CR23","doi-asserted-by":"crossref","unstructured":"Yang Y, Zhou T, Chen X et al. Efficacy, safety, and biomarker analysis of Camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study). J Immunother Cancer. 2021;9(12).","DOI":"10.1136\/jitc-2021-003790"},{"issue":"14","key":"1666_CR24","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","volume":"36","author":"BBY Ma","year":"2018","unstructured":"Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol. 2018;36(14):1412\u20138.","journal-title":"J Clin Oncol"},{"key":"1666_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.canlet.2020.02.010","volume":"477","author":"J Zhao","year":"2020","unstructured":"Zhao J, Guo C, Xiong F, et al. Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma. Cancer Lett. 2020;477:131\u201343.","journal-title":"Cancer Lett"},{"issue":"1","key":"1666_CR26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41467-021-21043-4","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, He S, Wang XL, et al. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. Nat Commun. 2021;12(1):741.","journal-title":"Nat Commun"},{"issue":"4","key":"1666_CR27","doi-asserted-by":"publisher","first-page":"EVIDoa2200239","DOI":"10.1056\/EVIDoa2200239","volume":"2","author":"GV Long","year":"2023","unstructured":"Long GV, Stephen Hodi F, Lipson EJ, et al. Overall survival and response with nivolumab and relatlimab in advanced melanoma. NEJM Evid. 2023;2(4):EVIDoa2200239.","journal-title":"NEJM Evid"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01666-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01666-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01666-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T12:12:21Z","timestamp":1738930341000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01666-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01666-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Presented in part at the 2024 American Association for Cancer Research (AACR), April 05, 2024 (abstract CT227).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}},{"value":"NCT05102006","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial information"}}],"article-number":"15"}}